Cash inflow leaned on NZ$1.1m working-capital release as loss narrowed only 6.1%

That release is the single largest swing factor in the result: debtor days dropped from 55.0 to 21.6, and inventories fell 39.0% to NZ$0.8m. It explains why operating cash flow rose from NZ$0.004m to NZ$0.351m despite the group still reporting a loss.

Revenue rose 10.2% to NZ$4.3m, the loss before tax narrowed 6.1% from -NZ$1.8m to -NZ$1.7m, and NPAT moved in lockstep (+6.1%) given a 0.0% effective tax rate in both periods. Cash on hand fell NZ$0.8m to NZ$8.8m and total equity contracted 19.5% to NZ$10.5m, so the balance sheet absorbed the period loss even with the working-capital tailwind.

• Pre-lease free cash flow of NZ$0.3m sits at the upper edge of the historical range, but the NZ$1.1m operating working capital release is unprecedented within the supplied baseline. Strip it out and the half would have been a ~NZ$0.7m cash burn, which is closer to the underlying run-rate implied by the -NZ$1.7m PBT.

• Revenue growth has slowed materially against history. The 10.2% print is below normal range versus an historical mean of 21.6% (range 11.4%–28.1%). This matters because the strategy reset announced in July 2022 has reprioritised toward B2B/ingredient licensing (the Probi blueprint), and the top line is not yet showing the acceleration that the new model is meant to deliver.

• The business remains structurally loss-making. PBT margin of -39.6% is well below the historical mean of -2.0% and below the prior range. Loss narrowing of 6.1% on 10.2% revenue growth implies very little operating leverage in this half, which raises the bar for the second half if the company wants to close the gap to break-even.

The only shape context available is FY22, where HY22 represented 43.4% of full-year revenue (a second-half-weighted pattern) and 66.4% of the full-year NPAT loss. Annualising the current half gives NZ$8.6m of revenue, below FY22's NZ$9.0m. The release does not support a claim that the company is on track to grow versus FY22, and it does not quantify when revenue re-acceleration or breakeven is expected. That gap matters because the strategy reset is the central management narrative and there is no disclosed milestone against which to measure execution.

The NZ$1.1m working-capital release came from receivables compression (debtor days down 33.4 days) and an inventory drawdown of NZ$0.5m. Annolyse's interpretation hint flags this as an unusually favourable release whose reversibility needs checking — and as ingredient/B2B revenue scales, both receivables and inventory typically rebuild, which means the cash benefit is unlikely to repeat at this magnitude.

On the earnings side, PBT and NPAT moved identically (the gap is 0.0 percentage points) because there is no tax line in either period, so there is no distortion masking the operating read. The cleaner read is therefore that a -39.6% PBT margin on slowing growth, combined with equity erosion of NZ$2.5m and cash burn of NZ$0.8m over six months, is the durable signal. FCF-to-NPAT of -18.4% looks favourable only because the denominator is a loss and the working-capital release is in the numerator.

This briefing cannot assess management's internal forecasts, partner pipeline visibility, or the durability of the working-capital release into the second half, as none of these are disclosed in the release.